Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/31448

Title:	Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study.
Authors:	Halcox, Julian P Banegas, José R Roy, Carine Dallongeville, Jean De Backer, Guy Guallar, Eliseo Perk, Joep Hajage, David Henriksson, Karin M Borghi, Claudio View more
Keywords:	Atherogenic dyslipidemia Cardiovascular disease Epidemiology Risk factors/global assessment View more
Mesh:	Aged Atherosclerosis Biomarkers Cardiovascular Diseases Cholesterol, HDL Cross-Sectional Studies Diabetes Mellitus, Type 2 Dyslipidemias Europe Female Guideline Adherence Humans Hypolipidemic Agents Male Middle Aged Practice Guidelines as Topic Practice Patterns, Physicians' Prevalence Primary Prevention Risk Factors Treatment Outcome Triglycerides View more
Issue Date:	2017
Citation:	BMC Cardiovasc Disord.2017 06;(17)1:160
Abstract:	Atherogenic dyslipidemia is associated with poor cardiovascular outcomes, yet markers of this condition are often ignored in clinical practice. Here, we address a clear evidence gap by assessing the prevalence and treatment of two markers of atherogenic dyslipidemia: elevated triglyceride levels and low levels of high-density lipoprotein cholesterol.
PMID:	28623902
URI:	https://hdl.handle.net/20.500.12530/31448
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos

Files in This Item:

File	Description	Size	Format
PMC5473961.pdf		983.8 kB	Adobe PDF	View/Open